Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline small index

Atrophy: full-pipeline trial registry

1 of 6 indexed Atrophy trials are currently recruiting.

Corpus placement: #2,866 of 28,707 conditions by registered trial count.

6 US clinical trials · 1 currently recruiting · #2,866 of 28,707 conditions by registered trial count

Atrophy: 6 US clinical trials tracked, 1 recruiting.

Atrophy is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Scholar Rock, running 3 of these trials.

Enrollment posture brief

Registry condition atrophy

OPEN 1 | RECR 17% | LATE 3 | EARLY 2 | RANK #2866 | SPON 3

Nearest open-share peer: Acute Renal Failure (17% recruiting · 6 trials)

Acute Hypoxemic Respiratory 66.7%Abdominal Aortic Aneurysms50%Acupuncture50%Acute Lymphoblastic Leukemia50%Atrophy (this)17%
Open-enrollment share among volume-matched conditions near Atrophy

Atrophy lists 1 open slots (17% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Atrophy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Atrophy is recruiting below its size-band peers.

    1 of 6 indexed trials (16.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Atrophy research.

    Scholar Rock accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Typical Atrophy enrolment sits around 188 participants.

    Median target enrolment is 188 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.

  4. Atrophy research is mostly interventional.

    6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 33

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 3

Top Sponsors

Named interventions

Most-linked intervention names on Atrophy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Apitegromab Drug
2 trials
Pixel CO2 Laser System Procedure
1 trials
Placebo cream Drug
1 trials
estrace cream (Reference) Drug
1 trials
estrace cream (Perrigo) Drug
1 trials
SRK-015 Biological
1 trials
CaLa Dietary supplement
1 trials
CaHMB (Dietary supplement, not Drug) Drug
1 trials

US sites by state

Facility locations filed on Atrophy trials. A trial with sites in several states counts in each.

Florida 4 trials
Oregon 3 trials
New York 3 trials
North Carolina 3 trials
Michigan 3 trials
Maryland 3 trials
Massachusetts 3 trials
Kansas 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Atrophy page

6 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Atrophy condition card totals 6 registered trials; most-linked intervention Apitegromab; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.